Abstract Search

ea0099p505 | Endocrine-Related Cancer | ECE2024

Growth differentiation factor 15 (GDF-15) is induced by mitotane in adrenocortical carcinoma and associated with poor prognosis and impaired responsiveness to immunotherapy

Weigand Isabel , Triebig Alexandra , Tanja Maier , Anderlik Tanja , Remde Hanna , Landwehr Laura-Sophie , Kimpel Otilia , Reuter Miriam , Schreiner Jochen , Wedekink Florian , Hoster Eva , Schwarzlmueller Paul , Reincke Martin , Wischhusen Jorg , Fassnacht Martin , Matthias Kroiss

Background: Treatment of adrenocortical carcinoma (ACC) is unsatisfactory in advanced stages. Oral mitotane remains a mainstay of treatment. Response rates of ACC to immune checkpoint inhibition (ICI) are disappointing and markers of response have not been identified. Tumoural infiltration with cells of the adaptive immune system is sparse in ACC tissue. Growth/differentiation factor 15 (GDF-15) is a cytokine that has been described to impair tumoral immune infiltration and is...

1 shares

Endocrine Abstracts

Growth differentiation factor 15 (GDF-15) is induced by mitotane in adrenocortical carcinoma and associated with poor prognosis and impaired responsiveness to immunotherapy

BiosciAbstracts